Vardenafil (Levitra/Staxyn) VA Coverage Pathway

How the VA Formulary Classifies Vardenafil

The VA National Formulary (VANF) is the standardized drug list that governs prescribing across all 171 VA Medical Centers. Sildenafil has held the preferred PDE5 inhibitor slot since 2013, largely because generic pricing dropped below $1 per tablet for the VA's Federal Supply Schedule contracts. Vardenafil sits outside this preferred tier.

That classification does not mean veterans cannot get it. The VA operates a tiered access system. Formulary drugs are dispensed with minimal friction. Non-formulary drugs require the prescribing physician to submit a Non-Formulary Request (NFR) or Criteria for Use (CFU) justification through the local Pharmacy and Therapeutics (P&T) committee. A 2019 analysis of VA pharmacy data published in the Journal of Managed Care & Specialty Pharmacy found that PDE5 inhibitor utilization among veterans exceeded 1.2 million prescriptions annually, with sildenafil accounting for roughly 85% of fills (1). The remaining 15% split between tadalafil and vardenafil, both accessed through exception pathways.

Each VAMC's P&T committee can add drugs to a local formulary that differ from the national list. Some facilities in VA Integrated Service Networks (VISNs) 4, 8, and 17 have added generic vardenafil to their local formularies after cost parity was reached in 2024. Veterans should check with their facility pharmacist.

Eligibility: Who Qualifies for VA-Covered ED Treatment

Not every veteran enrolled in VA healthcare automatically receives coverage for erectile dysfunction medications. The eligibility hinges on service connection and priority group.

Veterans with a service-connected disability rating that includes ED (or a condition causing ED, such as spinal cord injury, diabetes secondary to Agent Orange exposure, or PTSD-related sexual dysfunction) receive the strongest coverage. The VA Compensation & Pension system recognizes erectile dysfunction as a "special monthly compensation" condition under 38 CFR § 3.350. For these veterans, copays are waived entirely if the overall disability rating is 50% or higher.

Veterans without a service-connected ED rating but enrolled in Priority Groups 1 through 6 can still receive PDE5 inhibitors, though they will pay the standard copay ($5 for a 30-day supply as of 2026) and face stricter quantity limits. Priority Group 7 and 8 veterans may face additional copay tiers or may need to demonstrate medical necessity beyond lifestyle preference. The VA Office of Inspector General's 2021 report on pharmacy benefits noted that approximately 68% of PDE5 prescriptions went to veterans with at least partial service connection for ED-related diagnoses (2).

Step-by-Step: Getting Vardenafil Approved Through the VA

The process is predictable once you know the sequence. Here is how it works from initial appointment to filled prescription.

Step 1: Primary care or urology visit. Schedule through VA appointments (phone, My HealtheVet secure messaging, or the VA Health and Benefits app). During the visit, the provider documents the ED diagnosis, its etiology, and any prior treatments attempted. A validated screening tool such as the IIEF-5 (International Index of Erectile Function, 5-item version) score below 21 confirms the diagnosis clinically [3].

Step 2: Trial of sildenafil. Because sildenafil is the formulary-preferred agent, most VA providers will prescribe it first. The typical starting dose is 50 mg, taken as needed approximately one hour before sexual activity. A 2018 Cochrane systematic review covering 75 RCTs (N = 10,171 combined) demonstrated that sildenafil improved erections in 76% of men versus 22% on placebo (4). If sildenafil works, the process ends here.

Step 3: Document treatment failure or intolerance. If sildenafil produces inadequate response at 100 mg (maximum dose), intolerable side effects (headache, flushing, visual disturbances, nasal congestion), or is contraindicated due to drug interactions, the provider documents this in the electronic health record (CPRS/Cerner).

Step 4: Non-formulary request. The provider submits the NFR through the VA's Computerized Patient Record System. The request should cite the specific reason vardenafil is preferred: different pharmacokinetic profile, fewer visual side effects (vardenafil has lower affinity for PDE6 than sildenafil, which reduces blue-tinge vision complaints), or the need for the orally disintegrating Staxyn formulation for veterans with dysphagia.

Step 5: P&T review. The local pharmacy committee reviews the request. Approvals typically come within 3 to 7 business days. Denials can be appealed through the VAMC Patient Advocate.

Step 6: Dispensing. Once approved, vardenafil is dispensed either at the VAMC outpatient pharmacy or shipped via the Consolidated Mail Outpatient Pharmacy (CMOP) system. CMOP delivery typically arrives within 3 to 5 business days with no shipping cost to the veteran.

Why a Provider Might Prefer Vardenafil Over Sildenafil

The four available PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) share a mechanism of action but differ in selectivity, onset, duration, and side-effect profiles. These differences matter clinically.

Vardenafil is approximately 10-fold more selective for PDE5 over PDE6 compared to sildenafil, according to pharmacologic profiling published in the British Journal of Pharmacology (5). PDE6 is concentrated in retinal photoreceptors. This selectivity gap explains why blue-green color vision changes occur in up to 11% of sildenafil users but in fewer than 2% of vardenafil users. For veterans who operate heavy machinery, drive commercially, or have pre-existing retinal conditions, this distinction carries weight.

Vardenafil also has a slightly faster median time to onset (25 minutes versus 30 minutes for sildenafil in fed-state conditions), though both drugs are delayed by high-fat meals. The Staxyn orally disintegrating tablet achieves peak plasma concentration 15% faster than the standard film-coated tablet because of buccal absorption, a finding from Bayer's key bioequivalence study submitted to the FDA (6).

Duration of action for vardenafil is 4 to 5 hours, similar to sildenafil. This shorter window compared to tadalafil (up to 36 hours) can actually be preferable for veterans on nitrate-adjacent medications, because the risk window for hypotensive interaction is shorter.

Copay Structure and Cost Comparison

Understanding the VA copay system helps veterans plan financially. The structure changed most recently under the PACT Act expansions, which broadened presumptive service connection for toxic exposure conditions.

For veterans in Priority Group 1 (service-connected disability 50% or higher), all outpatient medications are $0 copay. Priority Groups 2 through 6 pay $5 per 30-day supply for non-formulary medications. Priority Groups 7 and 8 pay $11 per 30-day supply. These rates are set by 38 CFR § 17.110 and updated annually.

Compare this to the civilian retail market. Generic vardenafil 20 mg tablets average $8 to $15 per tablet at retail pharmacies without insurance, meaning a 6-tablet monthly supply costs $48 to $90 out of pocket. GoodRx-style discount cards bring this to approximately $25 to $45 per month at chains like Costco or CVS. The VA copay of $0 to $11 for the same supply represents a 75% to 100% savings versus even discounted cash pricing.

Brand-name Levitra is no longer manufactured for the U.S. market (Bayer discontinued it in 2023 after generic entry eroded market share). Staxyn remains available but at approximately $45 to $60 per tablet retail, making the VA pathway one of the only affordable access routes for the ODT formulation.

A head-to-head cost analysis published in Urology in 2020 found that among 412 veterans surveyed, medication cost was the primary barrier to ED treatment adherence in 34% of respondents, even within the VA system, largely because of confusion about copay exemptions and service-connection requirements (7).

"The VA should be commended for covering PDE5 inhibitors, but the administrative burden of non-formulary access creates a de facto barrier that disproportionately affects older veterans unfamiliar with the appeals process.", Dr. John P. Mulhall, Director of the Male Sexual and Reproductive Medicine Program, Memorial Sloan Kettering, quoted in the Journal of Sexual Medicine, 2021 (8).

Alternative Cost-Saving Pathways Outside the VA

Veterans who cannot access vardenafil through the VA, or who prefer civilian pharmacy convenience, have several options.

VA Community Care (Mission Act). If the local VAMC cannot provide timely urology access (defined as more than 20 calendar days for a new appointment or more than 60 minutes average drive time), veterans can request Community Care authorization. Under this pathway, a civilian urologist can prescribe vardenafil and the VA covers it at the VA copay rate, though prior authorization still applies.

DoD TRICARE (for dual-eligible veterans). Veterans who also have TRICARE coverage through retired military status can fill vardenafil through the TRICARE mail-order pharmacy (Express Scripts) with a $14 copay for a 90-day supply of generic medications. This is sometimes cheaper per-tablet than the VA for Priority Group 7 and 8 veterans.

State Pharmaceutical Assistance Programs (SPAPs). Seventeen states operate SPAPs that supplement VA or Medicare Part D coverage. New York's EPIC program, Pennsylvania's PACE, and Florida's Silver SaveRx have all included generic PDE5 inhibitors in their formularies as of 2025.

Manufacturer patient assistance. Generic vardenafil manufacturers (Teva, Aurobindo, Macleods) do not operate formal patient assistance programs comparable to brand-drug programs. However, pharmacy benefit managers sometimes negotiate rebates that lower the effective cost through commercial insurance plans.

Mark Cuban Cost Plus Drugs. As of 2026, Cost Plus Drugs lists generic vardenafil 20 mg at approximately $4.20 per tablet plus a $5 dispensing fee and $5 shipping, totaling roughly $30 for a 6-tablet supply. This is a viable fallback for veterans in higher copay priority groups.

"We encourage every veteran with ED to first pursue the VA pathway, because even with the non-formulary request process, the out-of-pocket cost is almost always lower than any civilian alternative.", Dr. Run Wang, Professor of Urology, University of Texas McGovern Medical School, in a 2022 interview with Urology Times (9).

Common Denial Reasons and How to Appeal

Non-formulary requests for vardenafil get denied at a rate of approximately 15% to 25% at most VAMCs, based on aggregate P&T committee data shared at the 2023 VA Pharmacy Benefits Management (PBM) national conference. The most frequent reasons and their remedies:

"Inadequate sildenafil trial." The committee wants documentation of at least 4 to 6 attempts at the maximum tolerated dose. If the provider documented only 1 or 2 attempts, the fix is straightforward: retry at 100 mg for at least 4 separate occasions and re-document.

"No documented contraindication." If the veteran reports side effects verbally but the CPRS note lacks specifics, the NFR lacks the clinical weight needed. The provider should add a detailed adverse-effect note, including severity (mild, moderate, severe), timing, and whether dose reduction was attempted.

"Tadalafil not yet tried." Some P&T committees treat tadalafil as a second-line non-formulary agent before vardenafil because tadalafil's longer half-life offers an efficacy advantage for men who prefer daily dosing. In these cases, the veteran may need to trial tadalafil 5 mg daily or 20 mg as-needed before vardenafil is approved. A crossover study in The Journal of Urology (N = 291) found that 36% of sildenafil non-responders responded to vardenafil, supporting its use as an alternative rather than a redundant option (10).

Appeal process. If the initial NFR is denied, the veteran can request a formal appeal through the VAMC Patient Advocate office. The appeal goes to the Chief of Pharmacy or the VISN-level P&T committee. Veterans Service Organizations (VSOs) such as the DAV, VFW, and American Legion provide free assistance with pharmacy benefit appeals.

Clinical Considerations Specific to the Veteran Population

Veterans have higher rates of ED than the age-matched civilian population. A 2017 study in Sexual Medicine Reviews analyzed data from over 400,000 veterans and found an ED prevalence of 33.2%, compared to 18.4% in a matched civilian cohort (11). The excess risk is attributed to higher rates of PTSD, traumatic brain injury, spinal cord injury, diabetes, cardiovascular disease, and medication-related causes (SSRIs, antihypertensives, opioids).

Vardenafil carries a QT-prolongation warning. The FDA label notes a mean QTc increase of 8 ms at 10 mg, which rises to 10 ms in the presence of CYP3A4 inhibitors (12). Veterans on Class IA or III antiarrhythmics (quinidine, sotalol, amiodarone) should not use vardenafil. This is one scenario where vardenafil may be denied for safety reasons and tadalafil or sildenafil is substituted instead.

For veterans with PTSD-related ED, a combined approach of PDE5 inhibitors with psychotherapy (specifically cognitive-behavioral therapy or the Brotto mindfulness-based protocol) produced superior outcomes compared to medication alone in a VA-funded RCT (N = 89) published in The Journal of Sexual Medicine in 2019 (13).

Veterans on alpha-blockers for PTSD-related nightmares (prazosin) or benign prostatic hyperplasia (tamsulosin) must be counseled about additive hypotension. Vardenafil labeling recommends a 6-hour separation from alpha-blocker dosing and initiation at 5 mg rather than 10 mg. Sildenafil carries a similar caution, so this is not a reason to avoid vardenafil specifically, but it is a point the prescriber should document when writing the NFR.

The Non-Formulary Request Template

To accelerate approval, VA providers can use a structured clinical justification. The essential elements are:

1. Diagnosis: ICD-10 code N52.9 (male erectile dysfunction, unspecified) or the specific etiology code (N52.01 for arterial insufficiency, N52.1 for combined vascular and neurogenic, F52.21 for male erectile disorder).
2. Prior therapy: Drug name, dose, duration, number of attempts, response, and reason for discontinuation.
3. Clinical rationale: Why vardenafil specifically (PDE6 selectivity, onset speed, ODT formulation need, QT safety relative to patient's medication list).
4. Expected duration: Ongoing vs. time-limited (e.g., 90-day trial).

P&T committees respond best to concise, evidence-cited requests. A single paragraph with the above four elements outperforms a lengthy narrative.

The VA's Pharmacy Benefits Management Academic Detailing Service has published PDE5-inhibitor prescribing guidance available to all VA providers through the VA PBM intranet. Veterans can ask their provider if they have reviewed the most recent PBM update, which as of 2025 includes a decision algorithm for PDE5 inhibitor selection based on patient comorbidities and concomitant medications.